Evidence map›Paper›PMID 31164120›Full record

ArticleCardiovascular diabetology2019

Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation.

Shehan N Randeria, Greig J A Thomson, Theo A Nell, Timothy Roberts, Etheresia Pretorius

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 6 pooled it
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 6 syntheses or guidelines pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Severe COVID-19: what have we learned with the immunopathogenesis?Advances in rheumatology (London, England) · 2020
    Pooled it
  7. Review
  8. Article
  9. Article
  10. Computational Modeling of Pro-inflammatory Cytokine-Enhanced Blood Coagulation.Computational and structural biotechnology journal · 2026
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Shehan N RanderiaDepartment of Physiological Sciences, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa.
Greig J A ThomsonDepartment of Physiological Sciences, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa.ORCID 0000-0002-8103-2455
Theo A NellDepartment of Physiological Sciences, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa.ORCID 0000-0003-3905-827X
Timothy RobertsDepartment of Physiological Sciences, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa. timothy-roberts@outlook.com.ORCID 0000-0002-1464-0151
Etheresia PretoriusDepartment of Physiological Sciences, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa. resiap@sun.ac.za.ORCID 0000-0002-9108-2384
Stellenbosch University · ZAUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe global burden of type 2 diabetes mellitus (T2DM), together with the presence of cardiovascular risk in this population, is reaching pandemic levels. A prominent feature of T2DM is chronic and systemic inflammation, with the accompanying presence of circulating and dysregulated inflammatory biomarkers; which in turn is associated with abnormal clot formation.

methodsHere, we investigate the correlation between abnormal blood clotting, using thromboelastography (TEG), clot ultrastructure using scanning electron microscopy (SEM) and the presence of a dysregulated inflammatory cytokine profile, by examining various circulating biomarkers.

resultsOur results show that many biomarkers, across TEG, cytokine and lipid groups, were greatly dysregulated in the T2DM sample. Furthermore, our T2DM sample's coagulation profiles were significantly more hypercoagulable when compared to our heathy sample, and ultrastructural analysis confirmed a matted and denser clot structure in the T2DM sample.

conclusionsWe suggest that dysregulated circulating molecules may in part be responsible for a hypercoagulable state and vascular dysfunction in the T2DM sample. We propose further that a personalized approach could be of great value when planning treatment and tracking the patient health status after embarking on a treatment regimes, and that looking to novel inflammatory and vascular biomarkers might be crucial.

Indexed as

Blood CoagulationBiomarkersCase-Control StudiesCross-Sectional StudiesCytokinesDiabetes Mellitus, Type 2FemaleHumansInflammation MediatorsMaleMicroscopy, Electron, ScanningMiddle AgedThrombelastographyThrombophiliaBiomarkersCytokinesInflammation MediatorsBiomarkersSystemic inflammationType 2 diabetes mellitusVascular dysfunction

Identifiers

PMID31164120
PMCPMC6549308
OpenAlexW2948646805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.